Trials / Completed
CompletedNCT01732614
Topcon Endpoint Management
Safety Assessment and Therapeutic Effect of Non-damaging Patterned Scanning Laser Phototherapy in Patients With Diffuse Diabetic Macular Edema
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Retinal Consultants of Arizona · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial seeks to prove that sub-lethal laser power levels are as effective and less damaging than traditional laser. Diabetic macular edema (DME) affects approximately 29% of diabetic patients with a disease duration of 20 or more years and is one of the most frequent causes of vision loss in this population. The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated a significant benefit of laser photocoagulation for the treatment of clinically significant macular edema, reducing the incidence of vision loss by approximately 50% at 3 years' follow-up.
Detailed description
Sub-visible, non-damaging visible laser (532 nm) exposures of 100 ms in duration resulted in enhanced expression of heat shock proteins in the retina. To test clinical efficacy of sub-visible retinal therapy using ms-range exposures of visible lasers one needs first to establish proper titration methods necessary to assure on one hand the lack of tissue damage, and on the other hand sufficient hyperthermia to elicit cellular response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Topcon Endpoint Management laser |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-11-01
- Completion
- 2013-12-01
- First posted
- 2012-11-26
- Last updated
- 2014-03-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01732614. Inclusion in this directory is not an endorsement.